MFN

News

As Democrats flip the Senate and House in a blue tsunami, we look at Trump's health and pharma policies that will likely see scrutiny and pushback.

News

US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.

Market Access

Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards MFN pricing.

News

PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation pricing in Medicare Part B in a US district court.

News

Public Citizen says claims for the drug price savings that are being delivered by Trump's Most-Favoured Nation deals with pharma are "a mirage."

Market Access

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.